Replies to post #141786 on Biotech Values

[mcbio]

PYMX—As you may recall, I never thought much of this heparin-reversal program and stated on several occasions that the idea had little commercial potential.

I can't award you full credit here as the heparin-reversal program appears to have been derailed by a safety issue, not a commercial issue. Will award partial credit for general bearishness though. ; )